retatrutide approval Tirzepatide vs. retatrutide approval 2025 Eli Lillys

GLP-3 Retatrutide is a novel investigational peptide being explored for its potential therapeutic benefits in metabolic disorders, particularly obesity and

Insurance coverage for GLP-1 medications for weight loss depends on diagnosis, plan type, and medical necessity criteria

If you have been diagnosed with NAION and used Ozempic or another GLP-1 medication, you may be entitled to substantial compensation.

Hims & Hers has released a white paper showing that 87% of its GLP-1 weight loss program customers are close to their goal or have met it.

Results After weighting, 24817 adults used a GLP-1 receptor agonist (mean age 59.9 years